Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Intellectual Equipoise and Challenges: Accruing Patients With Advanced Cancer to a Trial Randomizing to Surgical or Nonsurgical Management (SWOG S1316).

Deutsch GB, Deneve JL, Al-Kasspooles MF, Nfonsam VN, Gunderson CC, Secord AA, Rodgers P, Hendren S, Silberfein EJ, Grant M, Sloan J, Sun V, Arnold KB, Anderson GL, Krouse RS.

Am J Hosp Palliat Care. 2019 May 23:1049909119851471. doi: 10.1177/1049909119851471. [Epub ahead of print]

PMID:
31122027
2.

Lung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary Fibrosis.

O'Dwyer DN, Ashley SL, Gurczynski SJ, Xia M, Wilke C, Falkowski NR, Norman KC, Arnold KB, Huffnagle GB, Salisbury ML, Han MK, Flaherty KR, White ES, Martinez FJ, Erb-Downward JR, Murray S, Moore BB, Dickson RP.

Am J Respir Crit Care Med. 2019 May 1;199(9):1127-1138. doi: 10.1164/rccm.201809-1650OC.

PMID:
30789747
3.

Adipose-derived stem cell-secreted factors promote early stage follicle development in a biomimetic matrix.

Tomaszewski CE, Constance E, Lemke MM, Zhou H, Padmanabhan V, Arnold KB, Shikanov A.

Biomater Sci. 2019 Jan 29;7(2):571-580. doi: 10.1039/c8bm01253a.

PMID:
30608082
4.

Proteomics: Clinical and research applications in respiratory diseases.

Norman KC, Moore BB, Arnold KB, O'Dwyer DN.

Respirology. 2018 Nov;23(11):993-1003. doi: 10.1111/resp.13383. Epub 2018 Aug 13. Review.

5.

Lung Dysbiosis, Inflammation, and Injury in Hematopoietic Cell Transplantation.

O'Dwyer DN, Zhou X, Wilke CA, Xia M, Falkowski NR, Norman KC, Arnold KB, Huffnagle GB, Murray S, Erb-Downward JR, Yanik GA, Moore BB, Dickson RP.

Am J Respir Crit Care Med. 2018 Nov 15;198(10):1312-1321. doi: 10.1164/rccm.201712-2456OC.

PMID:
29878854
6.

Prospects from systems serology research.

Arnold KB, Chung AW.

Immunology. 2018 Mar;153(3):279-289. doi: 10.1111/imm.12861. Epub 2017 Dec 1. Review.

7.

Erratum: The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processes.

O'Dwyer DN, Norman KC, Xia M, Huang Y, Gurczynski SJ, Ashley SL, White ES, Flaherty KR, Martinez FJ, Murray S, Noth I, Arnold KB, Moore BB.

Sci Rep. 2017 Jun 30;7:46860. doi: 10.1038/srep46860.

8.

The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processes.

O'Dwyer DN, Norman KC, Xia M, Huang Y, Gurczynski SJ, Ashley SL, White ES, Flaherty KR, Martinez FJ, Murray S, Noth I, Arnold KB, Moore BB.

Sci Rep. 2017 Apr 25;7:46560. doi: 10.1038/srep46560. Erratum in: Sci Rep. 2017 Jun 30;7:46860.

9.

Systems analysis of dynamic transcription factor activity identifies targets for treatment in Olaparib resistant cancer cells.

Decker JT, Hobson EC, Zhang Y, Shin S, Thomas AL, Jeruss JS, Arnold KB, Shea LD.

Biotechnol Bioeng. 2017 Sep;114(9):2085-2095. doi: 10.1002/bit.26293. Epub 2017 May 18.

10.

Genital-Systemic Chemokine Gradients and the Risk of HIV Acquisition in Women.

Liebenberg LJ, Masson L, Arnold KB, Mckinnon LR, Werner L, Proctor E, Archary D, Mansoor LE, Lauffenburger DA, Abdool Karim Q, Abdool Karim SS, Passmore JS.

J Acquir Immune Defic Syndr. 2017 Mar 1;74(3):318-325. doi: 10.1097/QAI.0000000000001218.

11.

Sustained virologic control in SIV+ macaques after antiretroviral and α4β7 antibody therapy.

Byrareddy SN, Arthos J, Cicala C, Villinger F, Ortiz KT, Little D, Sidell N, Kane MA, Yu J, Jones JW, Santangelo PJ, Zurla C, McKinnon LR, Arnold KB, Woody CE, Walter L, Roos C, Noll A, Van Ryk D, Jelicic K, Cimbro R, Gumber S, Reid MD, Adsay V, Amancha PK, Mayne AE, Parslow TG, Fauci AS, Ansari AA.

Science. 2016 Oct 14;354(6309):197-202.

12.

Opportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial.

Goodman PJ, Tangen CM, Darke AK, Arnold KB, Hartline J, Yee M, Anderson K, Caban-Holt A, Christen WG, Cassano PA, Lance P, Klein EA, Crowley JJ, Minasian LM, Meyskens FL.

Trials. 2016 Aug 12;17:400. doi: 10.1186/s13063-016-1524-9.

13.

Peripheral Zone Inflammation Is Not Strongly Associated With Lower Urinary Tract Symptom Incidence and Progression in the Placebo Arm of the Prostate Cancer Prevention Trial .

Kulac I, Gumuskaya B, Drake CG, Gonzalez B, Arnold KB, Goodman PJ, Kristal AR, Lucia MS, Thompson IM, Isaacs WB, De Marzo AM, Platz EA.

Prostate. 2016 Nov;76(15):1399-408. doi: 10.1002/pros.23224. Epub 2016 Jun 21.

14.

Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel.

Archary D, Seaton KE, Passmore JS, Werner L, Deal A, Dunphy LJ, Arnold KB, Yates NL, Lauffenburger DA, Bergin P, Liebenberg LJ, Samsunder N, Mureithi MW, Altfeld M, Garrett N, Abdool Karim Q, Abdool Karim SS, Morris L, Tomaras GD.

Mucosal Immunol. 2016 May;9(3):834. doi: 10.1038/mi.2016.21. No abstract available.

PMID:
27116933
15.

Effect of long-term vitamin E and selenium supplementation on urine F2-isoprostanes, a biomarker of oxidative stress.

Guertin KA, Grant RK, Arnold KB, Burwell L, Hartline J, Goodman PJ, Minasian LM, Lippman SM, Klein E, Cassano PA.

Free Radic Biol Med. 2016 Jun;95:349-56. doi: 10.1016/j.freeradbiomed.2016.03.010. Epub 2016 Mar 22.

16.

Stepwise development of a cancer care delivery research study to evaluate the prevalence of virus infections in cancer patients.

Unger JM, Hershman DL, Arnold KB, Loomba R, Chugh R, Hwang JP, O'Rourke MA, Bhadkamkar NA, Wang LX, Siegel AB, Cooley TP, Berenberg JL, Bridges BB, Ramsey SD.

Future Oncol. 2016 May;12(10):1219-31. doi: 10.2217/fon-2015-0076. Epub 2016 Mar 8.

17.

Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel.

Archary D, Seaton KE, Passmore JS, Werner L, Deal A, Dunphy LJ, Arnold KB, Yates NL, Lauffenburger DA, Bergin P, Liebenberg LJ, Samsunder N, Mureithi MW, Altfeld M, Garrett N, Karim QA, Karim SA, Morris L, Tomaras GD.

Mucosal Immunol. 2016 May;9(3):821-833. doi: 10.1038/mi.2015.145. Epub 2016 Jan 27. Erratum in: Mucosal Immunol. 2016 May;9(3):834.

18.

Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology.

Chung AW, Kumar MP, Arnold KB, Yu WH, Schoen MK, Dunphy LJ, Suscovich TJ, Frahm N, Linde C, Mahan AE, Hoffner M, Streeck H, Ackerman ME, McElrath MJ, Schuitemaker H, Pau MG, Baden LR, Kim JH, Michael NL, Barouch DH, Lauffenburger DA, Alter G.

Cell. 2015 Nov 5;163(4):988-98. doi: 10.1016/j.cell.2015.10.027.

19.

Inflammatory cytokine biomarkers to identify women with asymptomatic sexually transmitted infections and bacterial vaginosis who are at high risk of HIV infection.

Masson L, Arnold KB, Little F, Mlisana K, Lewis DA, Mkhize N, Gamieldien H, Ngcapu S, Johnson L, Lauffenburger DA, Abdool Karim Q, Abdool Karim SS, Passmore JA.

Sex Transm Infect. 2016 May;92(3):186-93. doi: 10.1136/sextrans-2015-052072. Epub 2015 Oct 28.

PMID:
26511781
20.

CD4+ T cell-dependent and CD4+ T cell-independent cytokine-chemokine network changes in the immune responses of HIV-infected individuals.

Arnold KB, Szeto GL, Alter G, Irvine DJ, Lauffenburger DA.

Sci Signal. 2015 Oct 20;8(399):ra104. doi: 10.1126/scisignal.aab0808.

21.

Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Barrington WE, Schenk JM, Etzioni R, Arnold KB, Neuhouser ML, Thompson IM Jr, Lucia MS, Kristal AR.

JAMA Oncol. 2015 Jun;1(3):342-9. doi: 10.1001/jamaoncol.2015.0513. Erratum in: JAMA Oncol. 2015 Jun;1(3):322.

22.

Increased levels of inflammatory cytokines in the female reproductive tract are associated with altered expression of proteases, mucosal barrier proteins, and an influx of HIV-susceptible target cells.

Arnold KB, Burgener A, Birse K, Romas L, Dunphy LJ, Shahabi K, Abou M, Westmacott GR, McCorrister S, Kwatampora J, Nyanga B, Kimani J, Masson L, Liebenberg LJ, Abdool Karim SS, Passmore JA, Lauffenburger DA, Kaul R, McKinnon LR.

Mucosal Immunol. 2016 Jan;9(1):194-205. doi: 10.1038/mi.2015.51. Epub 2015 Jun 24.

PMID:
26104913
23.

Molecular Signatures of Immune Activation and Epithelial Barrier Remodeling Are Enhanced during the Luteal Phase of the Menstrual Cycle: Implications for HIV Susceptibility.

Birse K, Arnold KB, Novak RM, McCorrister S, Shaw S, Westmacott GR, Ball TB, Lauffenburger DA, Burgener A.

J Virol. 2015 Sep;89(17):8793-805. doi: 10.1128/JVI.00756-15. Epub 2015 Jun 17.

24.

Innate Antibacterial Activity in Female Genital Tract Secretions Is Associated with Increased Risk of HIV Acquisition.

Pellett Madan R, Masson L, Tugetman J, Werner L, Grobler A, Mlisana K, Lo Y, Che D, Arnold KB, Abdool Karim SS, Passmore JA, Herold BC.

AIDS Res Hum Retroviruses. 2015 Nov;31(11):1153-9. doi: 10.1089/AID.2015.0011. Epub 2015 Jul 14.

25.

Genital inflammation and the risk of HIV acquisition in women.

Masson L, Passmore JA, Liebenberg LJ, Werner L, Baxter C, Arnold KB, Williamson C, Little F, Mansoor LE, Naranbhai V, Lauffenburger DA, Ronacher K, Walzl G, Garrett NJ, Williams BL, Couto-Rodriguez M, Hornig M, Lipkin WI, Grobler A, Abdool Karim Q, Abdool Karim SS.

Clin Infect Dis. 2015 Jul 15;61(2):260-9. doi: 10.1093/cid/civ298. Epub 2015 Apr 21.

26.

A randomized controlled trial of vitamin E and selenium on rate of decline in lung function.

Cassano PA, Guertin KA, Kristal AR, Ritchie KE, Bertoia ML, Arnold KB, Crowley JJ, Hartline J, Goodman PJ, Tangen CM, Minasian LM, Lippman SM, Klein E.

Respir Res. 2015 Mar 11;16:35. doi: 10.1186/s12931-015-0195-5.

27.

Differential levels of soluble inflammatory markers by human immunodeficiency virus controller status and demographics.

Li JZ, Arnold KB, Lo J, Dugast AS, Plants J, Ribaudo HJ, Cesa K, Heisey A, Kuritzkes DR, Lauffenburger DA, Alter G, Landay A, Grinspoon S, Pereyra F.

Open Forum Infect Dis. 2015 Jan 13;2(1):ofu117. doi: 10.1093/ofid/ofu117. eCollection 2015 Jan.

28.

Retention of black and white participants in the selenium and vitamin E cancer prevention trial (SWOG-coordinated intergroup study S0000).

Arnold KB, Hermos JA, Anderson KB, Minasian L, Tangen CM, Probstfield JF, Cook ED.

Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2895-905. doi: 10.1158/1055-9965.EPI-14-0724. Epub 2014 Sep 21.

29.

Factors associated with adherence to an end-of-study biopsy: lessons from the prostate cancer prevention trial (SWOG-Coordinated Intergroup Study S9217).

Gritz ER, Arnold KB, Moinpour CM, Burton-Chase AM, Tangen CM, Probstfield JF, See WA, Lieber MM, Caggiano V, Moody-Thomas S, Szczepanek C, Ryan A, Carlin S, Hill S, Goodman PJ, Padberg RM, Minasian LM, Meyskens FL, Thompson IM Jr.

Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1638-48. doi: 10.1158/1055-9965.EPI-14-0202. Epub 2014 Jul 15.

30.

Enhanced immune activation linked to endotoxemia in HIV-1 seronegative MSM.

Palmer CD, Tomassilli J, Sirignano M, Romero-Tejeda M, Arnold KB, Che D, Lauffenburger DA, Jost S, Allen T, Mayer KH, Altfeld M.

AIDS. 2014 Sep 10;28(14):2162-6.

31.

HIV-1 infection induces strong production of IP-10 through TLR7/9-dependent pathways.

Simmons RP, Scully EP, Groden EE, Arnold KB, Chang JJ, Lane K, Lifson J, Rosenberg E, Lauffenburger DA, Altfeld M.

AIDS. 2013 Oct 23;27(16):2505-17. doi: 10.1097/01.aids.0000432455.06476.bc.

32.

Moving a randomized clinical trial into an observational cohort.

Goodman PJ, Hartline JA, Tangen CM, Crowley JJ, Minasian LM, Klein EA, Cook ED, Darke AK, Arnold KB, Anderson K, Yee M, Meyskens FL, Baker LH.

Clin Trials. 2013 Feb;10(1):131-42. doi: 10.1177/1740774512460345. Epub 2012 Oct 12.

33.

Finasteride reduces the risk of incident clinical benign prostatic hyperplasia.

Parsons JK, Schenk JM, Arnold KB, Messer K, Till C, Thompson IM, Kristal AR; Prostate Cancer Prevention Trial; Urologic Diseases in America Project.

Eur Urol. 2012 Aug;62(2):234-41. doi: 10.1016/j.eururo.2012.03.007. Epub 2012 Mar 14.

34.

Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial.

Schenk JM, Kristal AR, Arnold KB, Tangen CM, Neuhouser ML, Lin DW, White E, Thompson IM.

Am J Epidemiol. 2011 Jun 15;173(12):1419-28. doi: 10.1093/aje/kwq493. Epub 2011 May 3. Erratum in: Am J Epidemiol. 2011 Dec 15;174(12):1425.

35.

Linking plant growth responses across topographic gradients in tallgrass prairie.

Nippert JB, Ocheltree TW, Skibbe AM, Kangas LC, Ham JM, Arnold KB, Brunsell NA.

Oecologia. 2011 Aug;166(4):1131-42. doi: 10.1007/s00442-011-1948-6. Epub 2011 Mar 6.

PMID:
21380849
36.

Diet, supplement use, and prostate cancer risk: results from the prostate cancer prevention trial.

Kristal AR, Arnold KB, Neuhouser ML, Goodman P, Platz EA, Albanes D, Thompson IM.

Am J Epidemiol. 2010 Sep 1;172(5):566-77. doi: 10.1093/aje/kwq148. Epub 2010 Aug 6.

37.

Impact of supplemental site grants to increase African American accrual for the Selenium and Vitamin E Cancer Prevention Trial.

Cook ED, Arnold KB, Hermos JA, McCaskill-Stevens W, Moody-Thomas S, Probstfield JL, Hamilton SJ, Campbell RD, Anderson KB, Minasian LM.

Clin Trials. 2010 Feb;7(1):90-9. doi: 10.1177/1740774509357227.

38.

Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr.

JAMA. 2009 Jan 7;301(1):39-51. doi: 10.1001/jama.2008.864. Epub 2008 Dec 9.

39.

Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Kristal AR, Schenk JM, Song Y, Arnold KB, Neuhouser ML, Goodman PJ, Lin DW, Stanczyk FZ, Thompson IM.

Am J Epidemiol. 2008 Dec 15;168(12):1416-24. doi: 10.1093/aje/kwn272. Epub 2008 Oct 21.

40.

Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Goodman P, Penson DF, Thompson IM.

Am J Epidemiol. 2008 Apr 15;167(8):925-34. doi: 10.1093/aje/kwm389. Epub 2008 Feb 7.

PMID:
18263602
41.

Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Weiss N, Goodman P, Antvelink CM, Penson DF, Thompson IM.

J Urol. 2007 Apr;177(4):1395-400; quiz 1591.

PMID:
17382740
42.

Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Cook ED, Moody-Thomas S, Anderson KB, Campbell R, Hamilton SJ, Harrington JM, Lippman SM, Minasian LM, Paskett ED, Craine S, Arnold KB, Probstfield JL.

Clin Trials. 2005;2(5):436-42.

PMID:
16315648

Supplemental Content

Loading ...
Support Center